Axon’s margins are doing the limbo

The good news: EBITDA is climbing

Axon’s Q1 2026 update had a nice little flex in it: EBITDA rose 29.9%. That’s the sort of number that gets investors leaning in, because it suggests the company is still turning growth into actual operating muscle.

The not-so-fun part: the cost monster isn’t gone

But before everyone starts high-fiving, there’s a caveat. Management is still staring down cost pressure from tariffs and heavier investment spending. In other words: the revenue engine may be humming, but the pantry bill keeps going up.

Why investors should care

Margins are the whole ballgame here. If Axon can keep growing EBITDA while absorbing those cost headwinds, that’s a strong sign the business has some pricing power and operating leverage. If not, the market may start asking whether this growth story is getting more expensive to run than it used to be.

Big picture: good growth is nice, but profitable growth is nicer — and Axon is still proving it can keep both plates spinning.